On the other hand, dual HER2 blockade (e.g. Trastuzumab and Pertuzumab) is recommended to hormone receptor-negative and human epidermal growth factor 2-positive breast cancer (e.g. HER2-enriched) [8]. This evidence concerns the gene ERBB2 and breast carcinoma.